The amphetamine analog, 2,5-dimethoxy-4-methylamphetamine (DOM), was studied in 18 volunteer subjects given single doses ranging from 2 to 14 mg. The former was a threshold dose, with definite psychotomimetic effects being evident from doses over 5 mg. The clinical syndrome greatly resembled that of the LSD-mescaline-psilocybin series of drugs, including its time-course. Somewhat more sedation was produced by DOM than would have been expected from the others, despite concomitant evidence of peripheral sympathetic stimulation. Just as with the other drugs, DOM increased plasma free fatty acids, decreased phosphorus and creatinine clearance, decreased circulating eosinophils and had little effect on catecholamine excretion. Performance of psychometric tests was impaired. Chlorpromazine treatment concurrently was found to attenuate the reaction. Tolerance rapidly developed when the drug was used chronically by patients.
This is a preview of subscription content, log in via an institution to check access.
Access this article Subscribe and saveSpringer+ Basic
€34.99 /Month
Price includes VAT (Germany)
Instant access to the full article PDF.
Explore related subjectsDiscover the latest articles and news from researchers in related subjects, suggested using machine learning. ReferencesAlles, G. A.: Some relations between chemical structures and physiological action of mescaline and related compounds. Neuropharmacology. Josiah Macy, Jr., Foundation, Madison 1959.
Clyde, D. J.: Manual for the clyde mood scale. 15 pp. Univ. of Miami, Coral Gables, Fla., 1963.
Crout, J. R., and D. Abraham: Determination of 3-methoxy-4-hydroxymandelic acid in urine. Clin. chim. Acta 7, 285 (1962).
Hollister, L. E., and A. M. Hartman: Mescaline, lysergic acid diethylamide and psilocybin: Comparison of clinical syndromes, effects on color perception and biochemical measures. Comprehens. Psychiat. 3, 235 (1962).
— and B. M. Sjoberg, Jr.: Clinical syndromes and biochemical alterations following mescaline, lysergic acid diethylamide, psilocybin and a combination of the three psychotomimetric drugs. Comprehens. Psychiat. 5, 170 (1964).
— and A. J. Friedhoff: Effects of 3,4-dimethoxy-phenlyethylamine in man. Nature (Lond.) 210, 1377 (1966).
Moran, L. J.: Repetitive psychometric measures. Hogg Foundation for Mental Health, Austin, Texas 1959.
Shulgin, A. T.: 3-methoxy-4,5-methylenedioxy amphetamine, a new psychotomimetic agent. Nature (Lond.) 210, 1120 (1964).
Smythies, J. R., R. J. Bradley, V. S. Johnston, F. Benington, R. D. Morin, and L. C. Clark, Jr.: Structure-ac tivity relationship studies on mescaline III. The influence of the methoxy groups. Psychopharmacologia (Berl.) 10, 379 (1967).
Snyder, S. H., L. Faillace, and L. Hollister: 2,5-dimethoxy-4-methyl-amphetamine (STP): A new hallucinogenic drug. Science 158, 669 (1967).
Trout, D. L., R. H. Estes, Jr., and S. J. Friedberg: Titration of free fatty acids in plasma. A study of current methods and a new modification. J. Lipid Res. 1, 199 (1960).
M. F. Macnicol
Present address: Univ. of Edinburgh Medical School, UK
Veterans Administration Hospital Palo Alto, 94304, California, USA
Leo E. Hollister, M. F. Macnicol & H. K. Gillespie
Supported in part by Grant MH 03030, National Institute of Mental Health.
About this article Cite this articleHollister, L.E., Macnicol, M.F. & Gillespie, H.K. An hallucinogenic amphetamine analog (DOM) in man. Psychopharmacologia 14, 62–73 (1969). https://doi.org/10.1007/BF00401535
Received: 08 March 1968
Revised: 10 September 1968
Issue Date: January 1969
DOI: https://doi.org/10.1007/BF00401535
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4